15. A hybrid protein comprising one or more of the B1-B4 domains according to claim 14 which bind to the light chains in immunoglobulins of all classes, and domains which bind to heavy chains of immunoglobulin G.

- 16. A hybrid protein according to claim 15, wherein the domains which bind to heavy chains of immunoglobulin G are chosen from among the C1 and C2- domains in protein G; the A-, B- and C- domains in protein M1 or the E-, D-, A-, B- and C- domains in protein A.
- 17. A hybrid protein according to claim 16, wherein the hybrid protein has the amino acid sequence of Sequence I.D. No. 3.
- 18. A reagent kit for binding, separating and identifying immunoglobulins, comprising a protein according to any one of claims 14, 15, 16 or 17, and a detection reagent.
- 19. A composition, comprising a protein according to any one of claims 14, 15, 16 or 17 in combination with an additive or carrier.
- 20. A pharmaceutical composition, comprising a protein according to any one of claims 14, 15, 16 or 17 in combination with a pharmaceutically acceptable carrier or extender.

REMARKS

Claims 1, 3-5 and 11-13 have been cancelled without prejudice, and new claims 14-20 have been added. Based upon these amendments, claims 14-20 are now presently pending in the application.